SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Idorsia Enrolls First Patients in US QUVIVIQ Phase 3 Study

The Dari-Dream study targets daytime functioning claims for QUVIVIQ 50 mg, with results expected during 2028.

IDIA

Related stories